登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>TNFR2 >TN2-C52H7

Cynomolgus / Rhesus macaque TNFR2 / CD120b / TNFRSF1B Protein, His Tag

分子别名(Synonym)

TNFRSF1B,CD120b,TBPII,TNF-R-II,TNF-R75,TNFBR,TNFR1B,TNFR2,TNFR80,p75,p75TNFR

表达区间及表达系统(Source)

Cynomolgus / Rhesus macaque TNFR2, His Tag (TN2-C52H7) is expressed from human 293 cells (HEK293). It contains AA Leu 23 - Asp 257 (Accession # XP_005544817.1 ).

Predicted N-terminus: Leu 23

Request for sequence

蛋白结构(Molecular Characterization)

TNFR2 Structure

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 26.9 kDa. The protein migrates as 40-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

TNFR2 SDS-PAGE

Cynomolgus / Rhesus macaque TNFR2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

 

活性(Bioactivity)-ELISA

TNFR2 ELISA

Immobilized Biotinylated Human TNF-alpha, epitope tag free, primary amine labeling (Cat. No. TNA-H8211) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Cynomolgus / Rhesus macaque TNFR2, His Tag (Cat. No. TN2-C52H7) with a linear range of 0.6-10 ng/mL (QC tested).

Protocol

TNFR2 ELISA

Immobilized Cynomolgus / Rhesus macaque TNFR2, His Tag (Cat. No. TN2-C52H7) at 5 μg/mL (100 μL/well) can bind Biotinylated Human TNF-alpha, epitope tag free, primary amine labeling (Cat. No. TNA-H8211) with a linear range of 0.3-10 ng/mL (Routinely tested).

Protocol

TNFR2 ELISA

Immobilized Cynomolgus / Rhesus macaque TNFR2, His Tag (Cat. No. TN2-C52H7) at 5 μg/mL (100 μL/well) can bind Biotinylated Human TNF-alpha, His,Avitag (active trimer) (MALS verified) (Cat. No. TNA-H82E3) with a linear range of 0.2-10 ng/mL (Routinely tested).

Protocol

 

背景(Background)

TNF RI is also known as the p60 or p55 TNFR) and TNF RII (the p75 or p80 TNFR) are two distinct type I transmembrane glycoproteins that bind TNF with highaffinity.Both RI and RII are prototypic members of the TNF receptor superfamily and have been designated TNFRSF1A and TNFRSF1B, respectively. Human TNF RII cDNA encodes a 461 amino acid (aa) residue precursor protein with a 22 aa putative signal peptide, a 235 aa extracellular domain, a 20 aa transmembrane domain and a 174 aa cytoplasmic domain. TNFRII is expressed in fetal brain. The protein is produced naturally as a soluble form (sTNFRII). The soluble receptor inhibits TNFα action by competing with cell surface receptors in binding TNFα, thereby blocking its biologic effects. TNFRII is strongly expressed at the cartilage–pannus junction, and plays a major role in a subset of families with multiple cases of rheumatoid arthritis (RA). Further, high plasma levels of sTNFRII were significantly associated with increased incidence of coronary heart disease, independent of established cardiovascular risk factors, and seems to be useful for monitoring the inflammatory activity of sarcoidosis.

 

前沿进展

 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
TNFR2靶点信息
英文全称:Tumor necrosis factor receptor superfamily member 1B
中文全称:肿瘤坏死因子受体2
种类:Homo sapiens
上市药物数量:1详情
临床药物数量:6详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定